Labcorp and Children’s Hospital of Philadelphia (CHOP) announced plans to develop and commercialize specialty pediatric diagnostics. The collaboration is designed to move tests across areas including cancer, genetics, immune disorders, and rare diseases from development toward national availability. The agreement emphasizes accelerating the pathway between discovery and routine clinical use, an important constraint for pediatric-focused diagnostics where evidence generation and reimbursement can be challenging. Industry watchers will focus on the initial assay menus, clinical validation strategy, and the operational model for scaling pediatric testing through Labcorp’s network.